A preliminary version of Applied Biosystems' TaqMan drug metabolism genotyping assays is now available through an early-access customer programme.
A preliminary version of Applied Biosystems' TaqMan drug metabolism genotyping assays for the detection and study of polymorphisms in the drug metabolism pathway is now available through an early-access customer programme.
There are more than 2000 unique assays for the detection of genetic variants in more than 220 genes that code for drug metabolism enzymes.
Gene variants or polymorphisms in drug metabolism enzymes are important pharmaceutical biomarkers that play a key role in altering drug concentration levels and determining side effect profiles of drugs.
By characterising these polymorphisms, participants in clinical trials can be differentiated on a genetic basis into those who are likely to benefit from treatment and those who may experience adverse reactions.
The TaqMan drug metabolism genotyping assays are single-tube probe and primer sets for use on Applied Biosystems' real-time PCR instruments, including the 7300, 7500 and 7900HT real-time PCR Systems.
